MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Critical Care

Therapeutic Hypothermia at 35°C vs. Controlled Normothermia in ICU Heatstroke: Insights from a Pilot RCT

MedXY Editorial Team•Sep 3, 2026•Critical Care
chăm sóc hồi sức tích cựcHeatstrokekiểm soát thân nhiệt có mục tiêuTherapeutic Hypothermiaclinical trial

Highlight

This pilot randomized controlled trial examined targeted temperature management (TTM) at 35°C compared to controlled normothermia (36.5°C–37.5°C) in intubated adult heatstroke patients admitted to intensive care units (ICUs). The study demonstrated operational feasibility for a larger trial but revealed no differences in survival or neurological outcomes. However, therapeutic hypothermia was associated with significantly higher rates of severe gastrointestinal injury and cardiac arrhythmias. Additionally, universal and intensified pharmacologic treatment was required to control shivering in the hypothermia group, raising safety concerns. These findings suggest therapeutic hypothermia should not be routinely applied in ICU heatstroke management until further data confirm benefit and safety.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

12,13-diHOME Levels as a Marker of Brown Adipose Tissue Activation and Outcome in Targeted Temperature Management Post-Cardiac ArrestThis study reveals that elevated 12,13-diHOME levels, reflecting brown adipose tissue activation during targeted temperature management after cardiac arrest, correlate with improved survival and distinct immunometabolic profiles.Oct 21, 2026Phase 2 Trial of Icotrokinra for Patients with Ulcerative ColitisThis phase 2b trial demonstrates that oral icotrokinra, targeting the interleukin-23 receptor, significantly improves clinical outcomes in moderate to severe ulcerative colitis compared to placebo.Oct 20, 2026Pulse versus Nonpulse Corticosteroid Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Evidence Synthesis and Clinical Implications from the SAFER TrialThis review synthesizes current evidence on pulse versus nonpulse corticosteroid therapy in AE-IPF, contextualizing the SAFER trial findings within prior studies and clinical guidelines to guide management and future research.Oct 18, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Evaluating the Impact of a Digital Companion App in Periodontal Therapy: Insights from a Multi-Center Randomised Controlled Trial
A multi-center RCT assessing the adjunctive use of the Paro-ComPas app in periodontal care found no significant overall benefit, though moderate app engagement showed potential for improved plaque control.
Oct 16, 2026
Sonelokimab: A Promising Dual IL-17A/F Nanobody for Moderate-to-Severe Hidradenitis SuppurativaThe phase 2 MIRA trial shows sonelokimab, an IL-17A/F-inhibiting nanobody, significantly improves outcomes in moderate-to-severe hidradenitis suppurativa with good tolerability compared to placebo.Oct 16, 2026
Transforming Outcomes in Severe Tricuspid Regurgitation: Insights from the TRIC-I-HF TrialTranscatheter tricuspid-valve repair plus medical therapy significantly improves survival, reduces heart failure hospitalizations, and enhances quality of life in patients with severe tricuspid regurgitation compared to medical therapy alonOct 15, 2026